The world's biggest scientific documented health website for the happiness and health of your family, with science and faith we build the balance

108904791

Potent anti-obesity effect of enteric-coated lactoferrin: decrease in visceral fat accumulation in Japanese men and women with abdominal obesity.

Potent anti-obesity effect of enteric-coated lactoferrin: decrease in visceral fat accumulation in Japanese men and women with abdominal obesity.









No. Divisions/Titles for Abstract Details

1 Abstract Title Potent anti-obesity effect of enteric-coated lactoferrin: decrease in visceral fat accumulation in Japanese men and women with abdominal obesity after 8-week administration of enteric-coated lactoferrin tablets.


2 Abstract Source British journal of nutrition, 104, 1688-1695.


3 Abstract Author(s) Ono, T., Murakoshi, M., Suzuki, N., Iida, N., Ohdera, M., Iigo, M., Yoshida, T., Sugiyama, K. & Nishino, H.


4 Article Affiliation Research and Development Headquarters, Lion Corporation, Tajima 100, Odawara, Kanagawa 256-0811, Japan.


5 Abstract Lactoferrin (LF), a multifunctional glycoprotein in mammalian milk, is reported to exert a modulatory effect on lipid metabolism. The aim of the present study was to elucidate whether enteric-coated LF (eLF) might improve visceral fat-type obesity, an underlying cause of the metabolic syndrome. Using a double-blind, placebo-controlled design, Japanese men and women (n 26; aged 22–60 years) with abdominal obesity (BMI>25 kg/m2, and visceral fat area (VFA)>100 cm2) consumed eLF (300 mg/d as bovine LF) or placebo tablets for 8 weeks. Measurement of the total fat area, VFA and subcutaneous fat area from computed tomography images revealed a significant reduction in VFA ( − 14·6 cm2) in the eLF group, as compared with the placebo controls ( − 1·8 cm2; P = 0·009 by ANCOVA). Decreases in body weight, BMI and hip circumference in the eLF group ( − 1·5 kg, − 0·6 kg/m2, − 2·6 cm) were also found to be significantly greater than with the placebo (+1·0 kg, +0·3 kg/m2, − 0·2 cm; P = 0·032, 0·013, 0·041, respectively). There was also a tendency for a reduction in waist circumference in the eLF group ( − 4·4 cm) as compared with the placebo group ( − 0·9 cm; P = 0·073). No adverse effects of the eLF treatment were found with regard to blood lipid or biochemical parameters. From these results, eLF appears to be a promising agent for the control of visceral fat accumulation.


6 Summary Major sources of exogenous LF in our daily diet are dairy products from bovine milk. LF contents in bovine colostrum and normal milk are 1000 and 20–350mg/ml, respectively. The circulating LF concentration to be inversely associated with BMI, the waist:hip ratio and the fasting TAG and glucose concentrations, and positively with insulin sensitivity. They speculated that the preservation of LF production leads to decreased free lipopolysaccharide concentration and maintenance of an adequate lipid profile. Metabolic endotoxaemia initiates obesity and insulin resistance(31), and LF is known to bind to and inactivate lipopolysaccharide. Although, in the present study, we administered bovine LF extrinsically, there is a possibility that circulating LF could rise with oral administration of eLF, and neutralise the action of lipopolysaccharide.In summary, this trial clarified that the ingestion of eLF for an 8-week period can reduce visceral fat in men and women without the need for any lifestyle change. Additional analysis, with larger sample sizes, of this potential to prevent obesity and decrease risk of the metabolic syndrome is clearly warranted.


7 Article Published Date
09 August 2010.


8 Study Type a double-blind, placebo-controlled design.


9 Substances Colostrum.


10 Diseases Obesity.


11 Pharmacological Actions Lowering visceral fat / anti-obesity.


12 Link https://goo.gl/z6NP2J








videos balancecure


Share it



Subscribe with our newsletter


Comments

No Comments

Add comment

Made with by Tashfier

loading gif
feedback